Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis

Human Immunology

Volumn 74, Issue 2, 2013, Pages 166-169

  Tardito, Samuele ^a   Negrini, Simone ^a   Conteduca, Giuseppina ^a   Ferrera, Francesca ^a   Parodi, Alessia ^a   Battaglia, Florinda ^a   Kalli, Francesca ^a   Fenoglio, Daniela ^a,b   Cutolo, Maurizio ^b   Filaci, Gilberto ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ARTICLE; ASSAY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; PROLIFERATION SUPPRESSION ASSAY; REGULATORY T LYMPHOCYTE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

AGED; ALLELES; ANTIGENS, CD8; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY;

EID: 84872617225     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.11.008     Document Type: Article

References (22)

1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii3-7.
3. Romano E., Manetti M., Guiducci S., Ceccarelli C., Allanore Y., Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011, 29(Suppl 65):S75-86.
4. Fenoglio D., Battaglia F., Parodi A., Stringara S., Negrini S., Panico N., et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011, 139:249-257.
5. Long S.A., Buckner J.H. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011, 187:2061-2066.
6. Chung D.J., Rossi M., Romano E., Ghith J., Yuan J., Munn D.H., et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009, 114:555-563.
7. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4:1206-1212.
8. Mellor A.L., Munn D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008, 8:74-80.
9. Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010, 185:3190-3198.
10. Swanson K.A., Zheng Y., Heidler K.M., Mizobuchi T., Wilkes D.S. CD11c+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 2004, 30:311-318.
11. Vinay D.S., Kim C.H., Choi B.K., Kwon B.S. Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol 2009, 39:1552-1563.
12. Arefayene M., Philips S., Cao D., Desta Z., Flockhart D.A., Wilkes D.S., et al. Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics 2009, 19:464-476.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
14. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
15. Filaci G., Fravega M., Negrini S., Procopio F., Fenoglio D., Rizzi M., et al. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 2004, 65:142-156.
16. Filaci G., Cutolo M., Scudeletti M., Castagneto C., Derchi L., Gianrossi R., et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12months of therapy. Rheumatology (Oxford) 1999, 38:992-996.
17. Parodi N.M., Castagneto C., Filaci G., Murdaca G., Puppo F., Indiveri F., et al. Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. Br J Rheumatol 1997, 36:244-250.
18. Filaci G., Bacilieri S., Fravega M., Monetti M., Contini P., Ghio M., et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001, 166:6452-6457.
19. Godin-Ethier J., Hanafi L.A., Piccirillo C.A., Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011, 17:6985-6991.
20. Le A.V., Broide D.H. Indoleamine-2,3-dioxygenase modulation of allergic immune responses. Curr Allergy Asthm R 2006, 6:27-31.
21. Tan P.H., Bharath A.K. Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin Ther Tar 2009, 13:987-1012.
22. Ward A.J., Cooper T.A. The pathobiology of splicing. J Pathol 2010, 220:152-163.